hVIVO (LON:HVO) Trading Up 13% - What's Next?

Key Points

• hVIVO's stock price surged 13% during mid-day trading, reaching GBX 8 ($0.11) after trading approximately 9.6 million shares, marking a 223% increase in volume compared to the average daily volume.
• Analysts have varied price targets for hVIVO, with Peel Hunt setting a target of GBX 21 and Shore Capital lowering theirs to GBX 25, while the consensus rating remains a "Buy" with an average price target of GBX 23.
• hVIVO operates in the pharmaceutical sector, focusing on human challenge clinical trials for vaccines and antivirals, serving clients in big pharma, biotech, and government.

hVIVO plc (LON:HVO - Get Free Report)'s stock price rose 13% during mid-day trading on Monday . The stock traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). Approximately 9,588,585 shares traded hands during trading, an increase of 223% from the average daily volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analysts Set New Price Targets

HVO has been the subject of several research analyst reports. Peel Hunt reiterated an "add" rating and set a GBX 21 price target on shares of hVIVO in a report on Tuesday, July 29th. Shore Capital lowered their price target on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a report on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of GBX 23.

hVIVO Stock Up 13.0%

The firm has a market capitalization of £53.60 million, a price-to-earnings ratio of 1,012.99 and a beta of 0.97. The stock has a fifty day moving average of GBX 9.24 and a two-hundred day moving average of GBX 11.96. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.